The poor tumor growth and robust anti‐tumor immune mobilization seen in Usp44fl/fl Foxp3Cre+ mice illustrate how FOXP3‐stabilizing DUBs like USP44 may be tempting molecular targets for such future therapy. Here, FOXP3 is linked to neoplasm.